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Abstract
Interleukin 17–producing helper T cells (TH17 cells) have a major role in protection against 
infections and in mediating autoimmune diseases, yet the mechanisms involved are incompletely 
understood. We found that interleukin 26 (IL-26), a human TH17 cell–derived cytokine, is a 
cationic amphipathic protein that kills extracellular bacteria via membrane-pore formation. 
Furthermore, TH17 cell–derived IL-26 formed complexes with bacterial DNA and self-DNA 
released by dying bacteria and host cells. The resulting IL-26–DNA complexes triggered the 
production of type I interferon by plasmacytoid dendritic cells via activation of Toll-like receptor 
9, but independently of the IL-26 receptor. These findings provide insights into the potent 
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antimicrobial and proinflammatory function of TH17 cells by showing that IL-26 is a natural 
human antimicrobial that promotes immune sensing of bacterial and host cell death.
Human interleukin 17–producing helper T cells 7 (TH17 cells) are a subset of T cells that 
drive inflammatory responses by producing interleukin 17A (IL-17A), IL-17F, IL-21, IL-22 
and IL-26 (refs. 1–3). Defective TH17 cell responses in patients deficient in the transcription 
factor STAT3 have been associated with increased susceptibility to infection by 
Staphylococcus aureus and Streptococcus pyogenes4,5, which indicates that this T cell 
subset has a major role in the defense against extracellular bacterial infections, particularly 
in skin and mucosal surfaces. However, excessive TH17 cell responses can drive chronic 
inflammation and the development of autoimmunity in predisposed individuals. TH17 cell–
associated cytokines are indeed associated with disease activity and were found to be present 
in increased amounts in the skin of subjects with psoriasis, in the intestine of individuals 
with Crohn’s disease, in the brain of people with multiple sclerosis and in the synovium of 
people with rheumatoid arthritis and ankylosing spondylitis compared with healthy 
individuals6. Furthermore, variants of genes involved in IL-23–induced TH17 cell 
differentiation have been identified as susceptibility factors in psoriasis, multiple sclerosis, 
rheumatoid arthritis, ankylosing spondylitis and Crohn’s disease, which suggests a genetic 
basis for the enhanced TH17 cell responses in these diseases6.
The mechanisms by which TH17 cell cytokines drive antimicrobial and inflammatory 
responses are incompletely understood. IL-17A and IL-17F induce the expression of various 
CXC chemokines in epithelial cells, which drives the recruitment of neutrophils and 
monocytes7. IL-22 induces the proliferation of epithelial cells and is involved in epidermal 
remodeling8. IL-22 also cooperates with IL-17 to activate epithelial cells and induce the 
production of antimicrobial peptides8. IL-21 does not have a direct inflammatory role but 
amplifies and stabilizes the development of TH17 cells9. The functions of IL-26, a 19-kDa 
α-helical protein that belongs to the IL-20 cytokine family, are less well characterized. IL-26 
was first identified in herpesvirus saimiri–transformed T cells10 and was subsequently found 
to be conserved in most vertebrate species but absent in mice11. Like other TH17 cell 
cytokines, IL-26 shows high expression in psoriatic skin lesions1, colonic lesions from 
individuals with inflammatory bowel disease12 and synovia of individuals with rheumatoid 
arthritis13, and it is strongly associated with inflammatory activity. A risk locus containing 
IL26 and single-nucleotide polymorphisms within the IL26 gene region have been associated 
with multiple sclerosis14, rheumatoid arthritis15 and inflammatory bowel disease16, which 
suggests a particularly important role for IL-26 in TH17 cell–mediated inflammatory 
disease.
IL-26 signals through the IL-10R2–IL-20R1 heterodimeric receptor, which is expressed 
exclusively by epithelial cells17,18. Via its receptor, IL-26 inhibits the proliferation of 
intestinal epithelial cells and, in parallel, induces expression of immunosuppressive IL-10, 
but also of the proinflammatory cytokines tumor necrosis factor (TNF) and IL-8 (ref. 12). 
How these functions fit with the proinflammatory role of IL-26 in the context of TH17 cell 
responses remains unclear. Here we identified a distinctive cationic, amphipathic and 
multimeric structure of IL-26 that enabled TH17 cells to engage in direct antimicrobial 
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activity. This function was mediated by the ability of IL-26 to directly kill extracellular 
bacteria through pore formation. Furthermore, IL-26 was found to form complexes with 
extracellular DNA released by dying bacteria and host cells and to promote Toll-like 
receptor 9 (TLR9) activation of plasmacytoid dendritic cells (pDCs), providing evidence for 
a potent proinflammatory function of TH17 cells.
RESULTS
IL-26 is a cationic and amphipathic multimeric protein
Our sequence analysis of IL-26 showed unusual cationicity of this cytokine (calculated 
charge of +18.1 at pH 7 and isoelectric point of 10.4), as previously described17. The 
majority of the cationic charges were found to be contained in, or adjacent to, two of the six 
predicted helices of the protein, helices B and E, which contain three arginines and seven 
lysines (Supplementary Fig. 1a). Three-dimensional modeling of the protein showed that 
helices B and E were close to each other (Fig. 1a), which led to cluster formation and 
surface exposure of the cationic residues (Fig. 1b). On the opposite side of this cluster, we 
observed a hydrophobic patch (helix A) composed of several hydrophobic side chains 
(alanine 23, isoleucine 26, alanine 29, tryptophan 30 and alanine 33) (Fig. 1b). The 
predominance of polar (cationic) residues on one side of the molecule and hydrophobic 
amino acids on the opposite side indicated that IL-26 is a cationic amphipathic protein. In 
contrast, IL-22, a close homolog of IL-26 with 27% amino acid identity, has a net charge of 
+0.2 and an even distribution of cationic, anionic and hydrophobic residues across the 
surface of the molecule19 (Fig. 1b).
To gain further insights into the structure of IL-26, we carried out small-angle X-ray 
scattering analysis of recombinant human IL-26 (rhIL-26). IL-26 not only formed dimers but 
also was able to form higher-degree multimers (Fig. 1c and Supplementary Fig. 1b,c). This 
represented an atypical structure compared with close homologs IL-10 and IL-22, which can 
only dimerize. IL-26 multimers were found to adopt a beads-on-string shape (Fig. 1c and 
Supplementary Fig. 1b,c), which gave rise to elongated structures. This structure is distinct 
from the dimeric structure of IL-22, which is compact and results from extensive 
interactions among helices A, B and F of two monomers19. The structure of IL-26 is also 
distinct from the compact arm-exchange structure of IL-10 dimers20, which results from the 
exchange of helices E and F between two monomers. The absence of arm-exchange dimers 
in IL-26 is in agreement with the fact that proline 113 of IL-10, a key residue for the arm 
exchange in IL-10, is not conserved in IL-26. Moreover, the positions of IL-26 cysteines 11 
and 100 and of cysteines 58 and 103 in the 3D homology model suggest that these residues 
form two disulfide bonds to stabilize the helices of IL-26, rather than allowing an arm-
exchanged conformation (Supplementary Fig. 1d). Thus, IL-26 is a highly cationic and 
amphipathic protein that forms elongated multimers, representing a highly atypical structure 
compared with the structures of other cytokines from the same family. Because IL-26 
monomers or dimers would be sufficient for binding to the dimeric IL-26 receptor, the 
formation of multimeric structures suggests a functional adaptation of IL-26 to a specialized 
task.
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IL-26 kills extracellular bacteria by pore formation
Because an amphipathic structure, the clustering of cationic charges and the formation of 
multimers are hallmarks of naturally occurring antimicrobial peptides21, we asked whether 
IL-26 has antimicrobial properties. Using microbroth dilution assays, we found that 5–10 
μM rhIL-26 inhibited the growth of several gram-negative bacterial strains, including 
Pseudomonas aeruginosa (ATCC 27853, PA14), Escherichia coli (O1:K1:H7, O18:K1:H7, 
O111:B4, O111:K58:H2) and Klebsiella pneumoniae (O1:K2), as well as gram-positive S. 
aureus (ATCC 6538) (Fig. 2a and Supplementary Fig. 2a). No inhibition of colony 
formation was observed with Enterococcus faecalis or Candida albicans at IL-26 
concentrations up to 50 μM (Table 1). rhIL-26, but not rhIL-17 or rhIL-22, efficiently 
inhibited P. aeruginosa colony formation at a concentration of 10 μM (Fig. 2b). The 
observed inhibition of colony formation was due to bacterial killing, as the number of 
colonies decreased over time (>log 2 over 24 h) (Fig. 2c). A loss of membrane integrity was 
confirmed by decreased bacterial staining with a fluorescent membrane-potential indicator 
dye (Fig. 2d,e) and increased bacterial staining with an otherwise impermeable DNA dye 
(Supplementary Fig. 2b,c). IL-26 concentrations between 1 and 10 μM were required for 
bacterial killing, similar to the concentrations described for other cationic antimicrobial 
peptides such as LL-37 and hBD3 (Supplementary Fig. 2d,e). To determine whether IL-26, 
like other antimicrobial peptides, kills bacteria by pore formation and membrane disruption, 
we used scanning electron microscopy to analyze the ultrastructure of IL-26–treated 
bacteria. As early as 30 min after treatment with 10 μM IL-26, we observed the formation of 
membrane blebs on the surface of the bacteria (Fig. 2f). In some instances we observed 
disruption of the blebs with leakage of the cytosol into the extracellular environment (Fig. 
2f). These findings indicated that, similar to other cationic antimicrobial peptides, IL-26 
disrupts bacterial membranes via pore formation. Although the molecular basis for the 
interaction of IL-26 with gram-negative and gram-positive bacteria needs to be elucidated, 
we found that IL-26 had the ability to bind lipopolysaccharide (LPS) from gram- negative 
bacteria and lipoteichoic acid (LTA) from gram-positive bacteria (Fig. 2g and Table 2). 
Finally, we tested the antimicrobial activity of rhIL-26 in vivo using a mouse model of K. 
pneumoniae sepsis. This model uses intranasal administration of K. pneumoniae (O1:K2) to 
induce lung infection followed by rapid spreading of the bacteria into the circulation and the 
spleen22. Treatment of the mice with IL-26 resulted in significantly reduced bacterial titers 
in lungs, spleen and blood compared with amounts in control mice (Fig. 2h). The in vivo 
antibacterial activity of IL-26 was similar to that observed with the antimicrobial peptide 
LL-37. A strong reduction in bacterial titers was also observed when bacteria were 
pretreated in vitro with IL-26, before intranasal administration (Fig. 2h). Together, these 
data suggest that IL-26 is an antimicrobial protein that efficiently kills extracellular bacteria 
in vitro and in vivo.
TH17 cells induce antimicrobial effects via the production of IL-26
Microarray analysis of IL-26 expression on peripheral blood cell subsets showed that IL-26 
was expressed only on CD4+ T cells, and not on CD8+ T cells, NK cells, B cells, CD11c+ 
dendritic cells, pDCs, monocyte subsets or granulocytes (Supplementary Fig. 3a). In the 
CD4+ T cell subset, IL-26 seemed to be expressed mainly by TH17 cells, moderately by type 
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1 helper T cells (TH1 cells) and not at all by type 2 helper T cells (TH2 cells) 
(Supplementary Fig. 3a). To confirm these results, we carried out RT-PCR in in vitro–
differentiated TH17, type 0 helper T (TH0), TH1 and TH2 cells under well-established 
polarizing conditions23. We found that IL26 mRNA expression was indeed high in TH17 
cells and moderate in TH1 cells, but no expression was observed in TH0 or TH2 cells (Fig. 
3a). We then tested the ability of these supernatants to kill extracellular bacteria with a 
microbroth dilution assay. TH17 cell supernatants but not TH0 supernatants efficiently killed 
P. aeruginosa (Fig. 3b). Bacterial growth was completely restored by the addition of a 
blocking antibody to IL-26, which was shown to inhibit killing of bacteria by recombinant 
IL-26 (Fig. 2c–e). We also performed experiments with three different human TH17 cell 
clones (1G3, 7H1 and 72G6) and found that supernatants derived from activated clones 
killed bacteria efficiently (Fig. 3c). This activity was entirely dependent on IL-26, as small 
interfering RNA (siRNA)-mediated knockdown of IL-26 completely abrogated the ability of 
the TH17 cell clones to kill bacteria (Fig. 3c and Supplementary Fig. 3b). We noted that the 
concentration of IL-26 in the supernatants of both activated primary TH17 cells and 
activated TH17 cell clones ranged from 0.10 to 0.15 μM (Fig. 3d) and exerted roughly the 
same antimicrobial activity as 10 μM rhIL-26. This suggested that the natural IL-26 released 
by TH17 cell clones has an antimicrobial potency 80-fold to 120-fold greater than that of 
rhIL-26 (median minimum inhibitory concentration (MIC50) for rhIL-26 of 8.6 μM, versus 
0.068–0.1 μM for natural IL-26) (Supplementary Fig. 4a–c). Collectively these data 
demonstrate the direct antimicrobial capacity of TH17 cells enacted via their production of 
IL-26.
IL-26 promotes sensing of DNA released during bacterial killing
As clustered cationic charges in antimicrobial peptides have been shown to form complexes 
with extracellular DNA24, we asked whether IL-26 binds DNA during bacterial killing. 
Confocal microscopy of P. aeruginosa treated with rhIL-26 showed that dying bacteria 
released DNA structures that formed complexes with IL-26 (Fig. 4a). The ability of IL-26 to 
bind bacterial DNA was also confirmed when we mixed fragments of bacterial DNA with 
increasing concentrations of IL-26. IL-26, but not IL-17 or IL-22, efficiently bound to DNA, 
as shown by decreased staining of the DNA and retarded DNA migration in an agarose gel 
assay (Fig. 4b,c and Supplementary Fig. 5a). Furthermore, we found that bacterial DNA 
mixed with IL-26 formed insoluble particles, but DNA mixed with IL-17 or IL-22 did not 
(Fig. 4d and Supplementary Fig. 5b). This suggested that IL-26 is able to package and 
condense bacterial DNA. These IL-26–bacterial DNA particles were found to be highly 
protected from extracellular DNAse degradation (not shown), a process that has been shown 
to confer immunogenicity to DNA24–27.
To test whether IL-26–DNA complexes are immunogenic, we tested their ability to trigger 
the production of inflammatory cytokines by human peripheral blood mononuclear cells 
(PBMCs). IL-26–DNA complexes induced the production of IL-1β, IL-6 and interferon-α 
(IFN-α by PBMCs), but only the production of IFN-α was significantly enhanced compared 
with production after stimulation with bacterial DNA alone or IL-26 alone (Fig. 4e). To 
determine which cell type was responsible for the production of IFN-α, we stimulated 
monocytes, NK cells, neutrophils, pDCs and macrophages with IL-26–DNA complexes. 
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Only pDCs produced high amounts of IFN-α upon stimulation with complexes (Fig. 4f), and 
depletion of pDCs from PBMCs completely abrogated their ability to produce IFN-α, which 
indicated that pDCs are a key target of bacterial DNA–IL-26 complexes. Purified bacterial 
DNA alone induced weak or no IFN-α production by pDCs (Fig. 4f), and IL-26 was unable 
to induce any IFN-α production in pDCs in the absence of DNA (Fig. 4f and Supplementary 
Fig. 5c). Thus these data demonstrate that IL-26 can form complexes with bacterial DNA 
and thereby promote the immunogenicity of the DNA, leading to IFN-α production by 
pDCs. Next we tested whether IL-26–DNA complexes generated in the context of bacterial 
killing also promote pDC activation. Whereas live P. aeruginosa was unable to activate 
pDCs, P. aeruginosa killed by IL-26 induced strong IFN-α production (Fig. 4g). 
Supernatant of P. aeruginosa killed by freeze-thaw cycles was also unable to activate pDCs, 
but it acquired this ability when mixed with IL-26 (Fig. 4h). In these cultures, IFN-α 
production paralleled the DNA content (Fig. 4h and Supplementary Fig. 5d) and was 
completely abrogated when DNA was depleted by DNase treatment (Fig. 4i and 
Supplementary Fig. 5e). These findings indicate that IL-26 has the ability to kill bacteria, 
bind bacterial DNA and promote immunogenicity by triggering pDC activation.
IL-26 promotes sensing of human DNA released by dying cells
Because antimicrobial peptides can also promote the immunogenicity of human DNA24–27, 
we next asked whether IL-26 also kills human cells and promotes sensing of released self-
DNA. We tested the ability of rhIL-26 to kill a range of human cells, including human 
embryonic kidney (HEK) cells and primary immune cells, but we did not observe any 
cytotoxic activity at 10 μM, the concentration required for efficient microbial killing (Fig. 
5a). Similarly, rhIL-26 mixed with live human cells did not induce pDC activation (Fig. 5b). 
However, when rhIL-26 was mixed with irradiated human cells to trigger apoptosis and 
secondary necrosis, pDC activation was observed (Fig. 5b). As expected, pDC activation 
was dependent on extracellular DNA released by dying human cells, as it was largely 
abrogated by DNase treatment of the cultures (not shown). At higher rhIL-26 
concentrations, we detected cytotoxic activity on human cells similar to that described for 
other antimicrobial peptides such as LL-37 (Supplementary Fig. 6a,b). This in vitro 
cytotoxicity was observed at 4.9–6.6-fold the effective antimicrobial concentration for 
IL-26, compared to 4.0–7.6-fold that for LL-37 (Supplementary Fig. 6a,b).
We confirmed the ability of IL-26 to bind extracellular human DNA fragments and to form 
particulate complexes that resembled those described for bacterial DNA (Fig. 5c,d). Like 
IL-26–bacterial DNA complexes, IL-26–human DNA complexes induced preferential IFN-α 
production by PBMCs that was largely pDC dependent (Fig. 5e). Human DNA induced 
IFN-α production in a dose-dependent manner and only in the presence of IL-26 (Fig. 5e,f), 
which confirmed that IL-26 converts otherwise non-stimulatory human DNA into a potent 
activator of pDCs. IL-26–human DNA complexes were also found to induce some activation 
of monocytes, leading to the production of small amounts of IFN-α (Fig. 5e); this suggested 
broader action of IL-26 in DNA-mediated innate immune activation, potentially via 
cytosolic DNA sensors, as monocytes do not express TLR9. Furthermore, IL-26 alone was 
found to trigger the production of some IL-6 and IL-1β by purified monocytes, although this 
activity was intrinsic to IL-26 and was not enhanced by the presence of DNA (not shown). 
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Taken together, these data indicate that effective antibacterial concentrations of IL-26 are 
unable to kill human cells but do bind human DNA released in the context of cell death, 
leading to pDC activation.
IL-26–DNA complexes activate TLR9 in pDCs
Human pDCs specifically express TLR9, an endosomal receptor for DNA. To investigate 
whether IL-26 promotes immunogenicity of DNA by facilitating entry into TLR9-containing 
endosomal compartments, we first used fluorochrome-labeled DNA to track IL-26–DNA 
complexes in pDCs. We observed that IL-26–DNA complexes, but not DNA alone, rapidly 
associated with pDCs (Fig. 6a) and accessed intracellular vesicular structures in those cells 
(Fig. 6b). We concluded that internalization of the complexes occurred via endocytosis, as 
the vesicular structures expressed the early endosomal marker CD71 (Fig. 6b) and complex 
internalization was inhibited by culturing of pDCs either at 4 °C or in the presence of the 
endocytosis inhibitor Cytochalasin D (Fig. 6c,d).
Next we investigated how IL-26–DNA complexes are endocytosed by pDCs. These cells do 
not express the IL-20R1 chain28, which means that the IL-26 receptor cannot serve as a 
scavenger receptor. IL-26–DNA complexes were disrupted by the addition of increasing 
concentrations of the anionic molecule heparin (Supplementary Fig. 7a), which indicated 
that complex formation with the DNA is driven by the cationic residues of IL-26. Because 
polycation–nucleic acid complexes enter cells through heparan-sulfate proteoglycan 
(HSPG)-mediated endocytosis29, we investigated whether endocytosis of IL-26–DNA 
complexes is mediated by a similar mechanism. We found that internalization of the 
complexes was blocked both by pretreatment of pDCs with trypsin and by heparinase III 
(Fig. 6c,d), which suggested that HSPGs are required for membrane attachment and 
endocytosis by pDCs.
To determine whether, upon endosomal entry, IL-26–DNA complexes trigger activation of 
TLR9, we first measured IFN-α production by pDCs pretreated with chloroquine, an 
inhibitor of endosomal TLR signaling. IFN-α production was completely inhibited by 
chloroquine (Fig. 6e), which suggested the involvement of an endosomal TLR. IFN-α 
production was not inhibited when pDCs were treated with chloroquine and activated by 
cGAMP, which triggers the cytoplasmic sensor STING (Supplementary Fig. 8a). 
Furthermore, IFN-α production was not inhibited by a neutralizing antibody to IL-10R2 that 
blocks activation of the IL-26 receptor18 (Supplementary Fig. 8b) or by a STAT3 inhibitor 
that blocks IL-26–receptor signaling (not shown). Gain-of-function experiments using 
TLR9- and TLR4-transfected HEK293 cells confirmed that IL-26–DNA complexes induced 
NF-κB activation in TLR9-transfected HEK293 cells but not in TLR4-transfected cells (Fig. 
6f). Thus, we concluded that IL-26–DNA complexes are endocytosed by pDCs upon 
attachment to membrane HSPGs and trigger IFN-α production via activation of TLR9.
TH17 cells promote activation of pDCs by producing IL-26
TH17 cell supernatants containing concentrations of natural IL-26 sufficient to exert 
antimicrobial activity did not exert any cytotoxic activity on human cells (Fig. 5a). 
However, we observed that supernatants of re-stimulated TH17 cells contained insoluble 
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particles that stained for DNA and IL-26 (Fig. 7a), which suggested that TH17 cell–derived 
IL-26 forms complexes with endogenous DNA released in the context of cell turnover 
during cell culture. Consistent with the production of high amounts of IL-26 by TH17 cells, 
these particles were numerous in TH17 cell supernatants compared with their amounts in 
supernatants of other helper T cells, including TH0 cells (Fig. 7b). To determine whether 
these natural IL-26–DNA complexes present in TH17 cell supernatants trigger IFN-α 
production by pDCs, we stimulated purified pDCs with the TH17 cell supernatants. Half of 
the TH17 cell supernatants induced IFN-α production by pDCs (Fig. 7c,d), and this 
production was inhibited by the addition of an antibody to IL-26 that blocks binding to DNA 
(Supplementary Fig. 7b) and inhibits pDC activation (Supplementary Fig. 7c), as well as by 
DNase pretreatment of the supernatants (Fig. 7e). The other half of the TH17 cell 
supernatants, which did not activate pDCs, acquired the ability to induce IFN-α production 
when exogenous DNA was added to the culture (Fig. 7f), which indicated that the presence 
of endogenous DNA in TH17 cell supernatants was a limiting factor for pDC activation. 
Supernatants of TH17 cell clones expressing IL-26 were also able to induce IFN-α 
production by pDCs, and this was inhibited by siRNA-mediated knockdown of IL-26 (Fig. 
7g). The addition of exogenous DNA to the cultures enhanced interferon production by 
pDCs and confirmed that activation was driven by IL-26, as interferon production by pDCs 
was completely blocked in knockdown experiments (Fig. 7g). These findings suggest that 
TH17 cell–derived IL-26 drives innate immune activation of pDCs through the formation of 
complexes with human DNA released into the extra-cellular environment during cell 
turnover. We did not observe any differences between the concentration of natural IL-26 
contained in TH17 cell supernatants and the concentration of rhIL-26 required to induce 
IFN-α production in pDCs (Supplementary Fig. 4c). Both recombinant and natural IL-26 
induced IFN-α production by pDCs at 0.1 μM, a concentration that seems to be relevant in 
vivo, as tissue concentrations of up to 0.15 μM have been measured in psoriatic skin lesions 
known to contain large numbers of activated pDCs producing IFN-α (ref. 30) (Fig. 7h).
DISCUSSION
Our findings demonstrate an unexpected function of the human cytokine IL-26 in TH17 
cell–mediated antimicrobial and inflammatory responses. As predicted on the basis of its 
cationicity, amphipathicity and ability to form multimers, IL-26 exerted direct antimicrobial 
activity against extracellular bacteria. Like classical cationic antimicrobial peptides, IL-26 
forms pores in bacterial membranes, which leads to microbial lysis. Via the expression of 
IL-26, TH17 cells exert direct antimicrobial activity, and this provides new explanations for 
the known role of TH17 cells in the host defense. TH17 cells indeed mediate protection 
against extracellular bacteria: patients with defective TH17 cells are highly susceptible to S. 
aureus infections4, and mucosal TH17 cell depletion in the context of simian 
immunodeficiency virus infection leads to dissemination of gut bacteria31.
As a consequence of bacterial killing, TH17 cell–derived IL-26 also triggers potent immune 
activation. IL-26 binds to bacterial DNA released during the antimicrobial response and 
promotes internalization of the DNA into endosomal TLR9 compartments of pDCs, leading 
to the production of IFN-α. The mechanism underlying this process seems to be similar to 
the one described for the cationic antimicrobial peptide LL-37. First, IL-26 aggregates and 
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condenses DNA fragments to form insoluble particles that are protected from extra-cellular 
degradation. Second, exposed cationic residues enable attachment of the DNA complexes to 
heparan proteoglycans on the cell membrane, which leads to receptor-independent 
endocytosis. Finally, the DNA complexes gain access to endosomal TLR9, which leads to 
pDC activation and the production of high amounts of type I interferons.
During microbial infections, type I interferons (IFN-α and IFN-β) can have several 
functions. In the context of infections caused by intracellular bacteria, type I interferons can 
be detrimental because of their proapoptotic activity and their ability to interfere with anti-
bacterial mechanisms32–34. However, type I interferons can be beneficial in the context of 
infections by extracellular bacteria. Induction of type I interferon was shown to be 
associated with the resolution of P. aeruginosa lung infections35 and to be required for the 
control of infection by Group B streptococcus, Streptococcus pneumoniae and E. coli36. 
These effects might be driven by proinflammatory functions of type I interferons37 such as 
induction of dendritic cell maturation38,39, promotion of CD8+ T cell activation40,41 and 
TH1 cell differentiation41, activation of NK cells, and differentiation of B cells into 
antibody-secreting plasma cells42. Alternatively, type I interferon can also contribute to a 
beneficial disease outcome by downregulating certain inflammatory responses to bacterial 
infections. In fact, IFN-α production by pDCs seems to be responsible for controlling 
inflammation in a model of bacterial sepsis43. Given our findings, we speculate that IL-26 
might have evolved from a pure antimicrobial protein to become a potent trigger of IFN-α 
production that both amplifies and regulates innate and adaptive immune responses to 
extracellular bacteria.
IL-26 was also found to bind fragments of extracellular human (self-) DNA and trigger IFN-
α production via TLR9 activation in pDCs. This finding suggests that in addition to its 
antimicrobial role or as part of bacterial killing followed by binding of DNA, IL-26 also 
represents a danger signal that promotes IFN-α expression in injured tissue.
IL-26 is expressed in high amounts in TH17 cell–mediated autoimmune diseases such as 
psoriasis1, inflammatory bowel disease12 and rheumatoid arthritis13. These diseases are 
characterized by high numbers of pDCs and high IFN-α expression in tissues30,44,45, which 
suggests that IL-26 overexpression drives uncontrolled inflammatory responses via 
exaggerated IFN-α induction. As a consequence of this process, IL-26 may further enhance 
tissue injury by releasing self-DNA, leading to a self-sustaining inflammatory cycle that 
unleashes autoimmunity. Genetic evidence for a potential pathogenic role of IL-26 in these 
diseases is provided by the identification of a risk locus containing the gene IL26 and single-
nucleotide polymorphisms within the IL26 region in subjects with rheumatoid arthritis15 and 
inflammatory bowel disease16.
As is true of other antimicrobial peptides, high concentrations of recombinant IL-26 can kill 
normal human cells directly in vitro. In psoriasis, tissue concentrations of IL-26 were found 
to be relevant for antimicrobial and interferon-inducing activity, but not for cytotoxic 
activity against normal human cells. Although we cannot exclude the possibility that higher 
microconcentrations of IL-26 can occur in tissues, these data suggest that interferon 
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induction in vivo might be limited to situations in which host cells are destroyed by infection 
or inflammation and self-DNA is already present in the extracellular environment.
The regulation of IL-26 expression in TH17 cells is currently unknown. Analysis of in vitro–
generated helper T cell subsets suggests that IL-26 expression directly parallels the 
expression not of IL-17, but rather of IL-22. Distinct regulation of IL-26 expression is also 
suggested by the fact that bacteria and bacterial products that trigger IL-17 expression do not 
lead to increased expression of IL-26 in TH17 cells (data not shown).
Although pDCs seem to be the main target of IL-26–DNA complexes, we observed some 
activation of monocytes that led to the production of small amounts of IFN-α; this suggested 
broader implication of IL-26 in DNA-mediated innate immune activation, potentially via 
cytosolic STING-dependent DNA sensors as described for LL-37 (ref. 25). Future studies 
will be needed to determine whether, like LL-37, IL-26 can bind extracellular RNA 
fragments and trigger activation of conventional DCs and monocytes via TLR8 (ref. 46).
Our finding that the natural IL-26 in TH17 cell supernatants is more potent than recombinant 
IL-26 is consistent with previously documented differences in post-transcriptional 
modifications between natural and recombinant proteins, including glycosylation47. These 
differences were not observed for the IFN-inducing function of IL-26, which suggests that 
they are selectively required to promote the antimicrobial process, as suggested by others48. 
Another possibility is that IL-26 acts in synergy with other factors in TH17 cells to mediate 
antimicrobial activity.
In conclusion, this study showed that TH17 cells, via the production of IL-26, have direct 
antimicrobial activity and the ability to trigger potent immune responses via the expression 
of type I interferon. Future strategies could be developed to modulate IL-26 function, either 
to enhance host antimicrobial activity or to control inflammation in response to tissue injury 
and in the context of autoimmune diseases.
METHODS
Methods and any associated references are available in the online version of the paper.
ONLINE METHODS
Human samples
Studies were approved by the institutional review board of the University of Texas MD 
Anderson Cancer Center, the Heinrich-Heine University of Düsseldorf, and the University 
of Lausanne and were performed in accordance with the guidelines of the Declaration of 
Helsinki. Skin-punch biopsies were taken with informed consent from subjects with plaque 
psoriasis, defined according to standard clinical and histopathological criteria, and from 
healthy donors. Samples were snap-frozen and stored at −80 °C. Blood buffy coats from 
healthy donors were obtained from the Gulf Coast Regional Blood Center, Houston, Texas, 
or from the Service Vaudois de Transfusion, Epalinges, Switzerland.
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Reagents
Recombinant human IL-26 (rhIL-26)12,13,18, rhIL-17 and rhIL-22 were from R&D Systems. 
Human genomic DNA isolated from fetal skin, lung or leukocytes was from BioChain. 
Synthetic LL-37 and hBD3 were from Innovagen. To generate antibodies to IL-26, we 
immunized 6–8- week-old BALB/c mice with rhIL-26 protein. Hybridomas secreting 
antibodies specific for IL-26 were established. Two clones were used in these studies: clone 
142-84-1, with the ability to inhibit binding of IL-26 to DNA, and clone 142-69-1, with the 
ability to stain IL-26 for confocal microscopy. Both clones were used at 10 μg/ml. Mouse 
IgG1 isotype-matched antibodies were used as controls. Synthetic phosphothioate TLR9 
agonist CpG-2006 (1 μM) (5′-tcgtcgttttgtcgttttgtcgtt-3′) was from Trilink. The TLR1/2 
agonist Pam3CSK4, the TLR2 agonist LTA and the TLR4 agonist LPS were from 
Invivogen. Blocking goat anti-human IL-10R2 was from R&D Systems (AF874). 
Chloroquine was from Sigma.
Protein modeling
Human IL-26 models (UniProtKP sequence Q9NPH9) were generated using the software i-
Tasser49. Further modeling of IL-26 was based on published atomic structures of IL-19 
(PDB entry 1N1F) and IL-22 (1M4R), and a putative arm-exchanged IL-26 model was 
based on the atomic structure of IL-10 (2ILK). The sequences of IL-19, IL-22 and IL-10 are 
about 25% identical and about 55% similar to that of IL-26. The best i-Tasser model (a 
compact monomer) had a high-significance C-score of 0.36, with an expected r.m.s. 
deviation of 4.0 ± 2.7 Å.
Small-angle X-ray scattering (SAXS)
IL-26 was suspended in 16 mM sodium phosphate buffer, pH 6.5, 560 mM NaCl, 8% 
glycerol, 2 mM β-mercaptoethanol and then concentrated to 1.1 mg/ml. Data were recorded 
at the ALS (Berkeley, CA) beamline 12.3.1. (SIBYLS) at 10 °C using a wavelength of 1 Å, 
for values of the momentum transfer vector q = (4πsinθ)/λ between 0.01 and 0.32 Å−1. The 
same sample was sequentially exposed to X-rays for 0.5 s, 1 s and 5 s. Samples containing 
buffer only were measured before and after protein samples. The buffer contributions were 
subtracted from protein scattering data with the Ogre software program available at 
SIBYLS. Data were not affected by radiation damage, as indicated by a constant Rg of the 
Guinier region for subsequent sample exposures. We obtained a combined SAXS pattern by 
scaling and merging selected regions of buffer-subtracted scattering patterns for the 0.5-s, 1-
s and 5-s exposures. Data with q values between 0.01 and 0.13 Å−1 were analyzed with 
PRIMUS, SASREF and DAMMIF of the ATSAS software package50.
Antimicrobial assays
The following bacteria strains were used: Pseudomonas aeruginosa (ATCC 27853 and 
PA14), Escherichia coli (O1:K1:H7, O18:K1:H7, O111:K58:H2 and J5 O111:B4), 
Staphylococcus aureus (ATCC 6538), Klebsiella pneumoniae (O1:K2), and Enterococcus 
faecalis (ATCC 29212). Bacteria were cultured at 37 °C overnight in trypticase soy broth 
with 10 mM NaCl and then subcultured for an additional 3 h to achieve mid–logarithmic 
phase growth. Bacterial concentrations were measured by spectrophotometry at 620 nm and 
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diluted to a final concentration of 105 CFU/ml, after which they were incubated at 37 °C for 
24 h under low-ionic-strength conditions (10 mM NaCl). IL-26, LL-37 and hBD3 were 
added to these cultures to test their antimicrobial activity. After 24 h, serial dilutions of 
bacterial cultures were plated onto lysogeny broth (LB) agar plates. The number of colonies 
formed after overnight incubation was counted by two independent investigators. The 
MIC50 of IL-26 was defined as the lowest concentration that inhibited >50% of the growth 
of bacteria after overnight incubation. In some experiments, bacteria were incubated in 
antibiotic-free RPMI medium or TH17 cell supernatants supplemented or not with the 
blocking anti–IL-26 clone 142-84-1 at 10 μg/ml. For analysis of the membrane potential 
loss, bacteria were incubated with 10 μM IL-26 and harvested at different time points to be 
stained with the fluorescent membrane-potential indicator dye DiOC2(3) (BacLight bacterial 
membrane potential kit, Molecular Probes) according to the manufacturer’s protocol. As a 
positive control, we used 5 μM CCCP, a proton ionophore. For further analysis of bacterial 
death, we stained bacterial nucleic acids with 5 μM cell-permeant SYTO 13 Green dye and 5 
μM cell-impermeant SYTOX Orange dye (Life Technologies). Viable bacteria will be 
stained by SYTO 13 Green but not SYTOX Orange, whereas dead bacteria will be stained 
with both dyes.
Scanning electron microscopy of P. aeruginosa
We incubated 5 × 105 CFU of P. aeruginosa with IL-26 or vehicle (sodium phosphate, 1.0 
M NaCl, 10% glycerol, pH 6.5) for 30–180 min in trypticase soy broth. Samples were 
placed on poly-L-lysine–treated glass coverslips and allowed to dry overnight. Samples on 
coverslips were mounted onto double-stick carbon tabs (Ted Pella) that had been previously 
mounted on aluminum specimen mounts (Electron Microscopy Sciences). The samples were 
then coated under vacuum with a Balzer MED 010 evaporator (Technotrade International) 
with platinum alloy to a thickness of 25 nm, after which they were immediately flash–
carbon coated under vacuum. The samples were transferred to a desiccator for examination 
at a later date. Samples were examined in a JSM-5910 scanning electron microscope (JEOL) 
at an accelerating voltage of 5 kV.
ELISA binding assay
Nunc MaxiSorp 96-well plates were coated with PBS 1% BSA, 1 μg/ml LPS or 1 μg/ml 
LTA for 24 h at 4 °C. Plates were then washed, and increasing concentrations of IL-26, 
LL-37 or IL-22 diluted in PBS 1% BSA were added for 1 h at room temperature. Plates 
were then washed, and 0.5 μg/ml of mouse anti–IL-26 (clone 142-69-1), anti–LL-37 
(sc-166770, Santa Cruz Biotechnology) or anti–IL-22 (clone 142906; MAB7822, R&D 
Systems) diluted in PBS 1% BSA was added for 1 h at room temperature. Plates were then 
washed, and horseradish peroxidase–conjugated goat anti-mouse IgG (Thermo Scientific) 
diluted 1/5,000 in PBS 1% BSA was added to all wells for 30 min at room temperature. 
Plates were then washed, and TMB substrate was added. Plates were then read at 450 nm 
with a spectrometer.
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In vivo lung infection model
Animal procedures were approved by the Office Vétérinaire du Canton de Vaud, Lausanne, 
Switzerland, and performed according to the Swiss federal guidelines for animal 
experimentation. K. pneumoniae strain Caroli (O1:K2)22 was cultured at 37 °C overnight in 
10 ml brain-heart infusion medium, subcultured for 2 h, and further diluted to obtain 104 
CFU/ml. Eight-week-old female BALB/c mice (Harlan Lab) were used. We administered 
102 CFU of K. pneumoniae intranasally (i.n.) in a volume of 10 μl by holding the mice in an 
upright position under anesthesia. After infection, one of the following in a 20-μl volume 
was administered i.n.: 20 μg of IL-26, 50 μg LL-37 (positive control) or PBS (negative 
control). Another control condition was intranasal infection of mice with IL-26–pretreated 
bacteria (102 CFU + 20 μg IL-26 mixed for 1 h before administration). Seventy-two hours 
post-challenge, mice were euthanized, and blood, lungs and spleen were collected. Lungs 
and spleens were weighed and homogenized with a Potter-Elvehjem Pestle. Diluted blood, 
lung and spleen homogenates in NaCl were cultured overnight on blood agar plates before 
bacterial colonies were counted by two independent investigators.
Isolation of peripheral blood cells
Peripheral blood mononuclear cells (PBMCs) were obtained by Ficoll centrifugation of 
blood buffy coats. Monocytes, NK cells, and pDCs were then isolated by magnetic 
separation with the following commercially available kits: Monocyte Isolation Kit II 
(Miltenyi), EasySep Human NK Cell Enrichment Kit (StemCell), and Diamond pDC 
Isolation Kit II (Miltenyi). We differentiated macrophages by culturing monocytes with 50 
ng/nl of the cell-signaling molecule GM-CSF for 5 d. After Ficoll centrifugation, we used 
the high-density granulocyte fraction to isolate neutrophils with CD15 Microbeads 
(Miltenyi). Purity was routinely >95%, as assessed by flow cytometry of CD14+ monocytes, 
CD56+ NK cells, BDCA2+CD123+ pDCs, CD14+CD68+FSChi macrophages and 
CD15+SSChi neutrophils.
Microarray analysis
Total RNA from sorted cells was immediately isolated with the RNeasy kit from Qiagen and 
used to generate cDNA according to the Expression Analysis Technical Manual 
(Affymetrix). cRNA samples were generated with the Bioarray High-Yield RNA Transcript 
Labeling kit (Enzo) and the Human Genome U133 Plus 2.0 array according to the 
manufacturer’s protocol (Affymetrix). The scanned images were aligned and analyzed with 
GeneChip Microarray Suite 5.0 (Affymetrix) according to the manufacturer’s instructions. 
The signal intensities were normalized to the mean intensity of all the genes represented on 
the array, and global scaling (to all probe sets) was done before comparison analysis. Genes 
with variable expression levels were selected on the basis of the following criteria: gene 
expression (i.e., presence calls) in at least one of the three samples, and a σi/μi ratio of >0.65, 
where σi and μi are the s.d. and mean of the hybridization intensity values of each particular 
gene across all samples, respectively.
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In vitro generation and characterization of IL-26–DNA complexes
We generated IL-26–DNA complexes by mixing 600 ng of bacterial DNA (Life 
Technologies) or human DNA (BioChain) with different concentrations of recombinant 
IL-26 in 40 μl of nuclease-free water (Ambion) and then diluted them into 200 μl of 
complete medium for cell stimulation (final concentrations: 3 μg/ml DNA and 0.1–1 μM 
IL-26). IL-26–DNA complexes were visualized by 1.5% agarose gel migration or by 
confocal microscopy after DNA had been stained with DAPI (0.1 ng/ml; Sigma-Aldrich) or 
labeled with Alexa Fluor 488. DNA labeling with Alexa Fluor 488 was done with the Ulysis 
Nucleic Acid Labeling Kit (Molecular Probes), which uses a platinum dye complex to form 
a stable adduct with the N7 position of a guanine and, with less efficiency, with adenine 
bases in DNA. For detection of IL-26, suspensions containing precipitating complexes were 
stained overnight with mouse anti–IL-26 (clone 142-69-1), carefully washed, and incubated 
with Alexa Fluor 546–labeled anti-mouse secondary antibody for 1 h.
Generation of TH17 cells and TH17 cell clones
CD4+ naive T cells were enriched from buffy coats of healthy volunteers with the CD4+ 
Naive T Cell Isolation Kit II (Miltenyi Biotec). Afterward, the cells were sorted on a 
FACSAria (Becton Dickinson) as CD45RA+, CD4+, CD8−, CD14−, CD16−, CD20−, 
CD56−, γδTCR−, BDCA2−, CD11c−, CD25−, or CD45RO− to reach a purity of >95% naive 
CD4+CD45RA+ T cells. These cells were then plated in flat-bottom plates at 5 × 104 cells/
well and cultured for 5 d in the presence of plate-bound anti-CD3 (10 μg ml−1) and soluble 
anti-CD28 (1 μg ml−1) + IL-1β (10 ng/ml) + IL-6 (20 ng/ml) + TGF-β (1 ng/ml) + TNF-α 
(10 ng/ml) + IL-23 (100 ng/ml) in Yssel’s medium (Gemini)23. As a control, we also 
stimulated naive T cells (i) without cytokines; (ii) with IL-12 (5 ng/ml), IFN-γ (20 ng/ml) 
and anti–IL-4 (10 μg/ml); and (iii) with IL-4 (25 ng/ml) and anti–IFN-γ (10 μg/ml) to 
generate TH0, TH1 and TH2 cells, respectively. All cytokines used for polarization were 
purchased from R&D Systems. For the TH17 cell clones, 1G3, 7H1 and 72G6 cells were 
generated as described previously and cultured in RPMI 1640 medium (Invitrogen) 
supplemented with 2 mmol/L L-glutamine, 0.05 mmol/L β-mercaptoethanol, 10% human 
male AB serum (GemCell), 300 IU/mL IL-2, 5 ng/mL IL-1β and 10 ng/mL IL-23 in the 
presence of the irradiated feeder EBV B cell line LCL111 at 0.3 × 106/mL. To generate 
supernatants, we re-stimulated primary TH17 cells or TH17 cell clones with anti-CD3 or 
anti-CD28 in antibiotic-free medium and harvested cell-free supernatants 24 h later. IL-26 
protein levels in TH17 cell supernatants were measured by ELISA (USCN Life Science). In 
some experiments, TH17 cell clones were transfected at 37 °C for 6 h with 80 pmol of 
control siRNA-A (scrambled sequence) or siRNA targeting IL-26 complexed with 6 μl of 
siRNA Transfection Reagent according to the manufacturer’s protocol (Santa Cruz 
Biotechnology). Cells were then washed and re-stimulated with anti-CD3 or anti-CD28 in 
antibiotic-free medium, and cell-free supernatants were harvested 24 h later. The IL-26 
concentration in the different supernatants was measured by ELISA (Cusabio Biotech).
Real-time PCR analysis
Polarized TH0, TH1, TH2, and TH17 cells were harvested, lysed with TRI Reagent 
(Ambion), and stored at −20 °C. Total RNA was extracted with the RiboPure kit (Ambion) 
Meller et al. Page 14
Nat Immunol. Author manuscript; available in PMC 2016 March 03.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
and cleaned with the RNAqueous kit (Ambion). One microgram of RNA was then reverse-
transcribed into cDNA (High Capacity cDNA, Applied Biosystems). For each individual 
gene, 20 ng of cDNA was amplified for expression analysis with TaqMan on an ABI 7500 
Fast system. Human GAPDH mRNA levels were quantified and used for normalization as 
described30. Human TaqMan probes used were IL26 (Hs00218189_m1), IL17A 
(Hs00174383_m1), IL17F (Hs00369400_m1), IL22 (Hs01574154_m1), IFNG 
(Hs00989291_m1) and IL13 (Hs00174379_m1), all from Life Technologies.
Imaging of IL-26–DNA complexes in TH17 cell supernatants
We visualized DNA–IL-26 complexes in TH17 cell supernatants by staining precipitating 
complexes with 10 μg/ml mouse anti–IL-26 (clone 142-69-1) for 2 h and then incubating 
them with Alexa Fluor 546–labeled anti-mouse secondary antibody for 1 h. After washing, 
DAPI (0.1 ng/ml) was added to stain DNA and visualized by confocal microscopy.
Stimulation of immune cells by IL-26–DNA complexes or TH17 cell supernatants
Purified immune cells were cultured in 96-well round-bottom plates at 5 × 104 cells/well in 
200 μl RPMI 1640 medium (Gibco) supplemented with 10% FCS (Atlanta Biologicals) and 
penicillin-streptomycin in the presence of 1 μM IL-26, bacterial DNA or human DNA, or 
with IL-26–DNA complexes. The viability of cells after culture was assessed by flow 
cytometry with 7-AAD staining according to the manufacturer’s protocol (BioLegend). In 
some experiments, pDCs were stimulated with different amounts of live bacteria (P. 
aeruginosa), different concentrations of DNA content from chemically lysed bacteria (50 
mM Tris, pH 8.0, 0.1% Triton X-100) or different amounts of live or UV-treated dying 
HEK293T cells (1 × 106 cells/ml) in the presence of 10 μM IL-26. The HEK293T cell line 
was from ATCC (CRL-11268). Cell cultures were routinely tested for mycoplasma 
contamination. pDCs were also stimulated with various amounts of supernatants derived 
from TH0 or TH17 cells alone or supplemented with 3 μg/ml human DNA. In some 
experiments the supernatants or in vitro–generated complexes were pretreated with DNase I 
(1,000 U/ml) or heparin (up to 10 U/ml).The different immune-cell supernatants were 
collected after overnight culture, and the levels of cytokine production (IL-1β, IL-6, TNF-α 
(R&D Systems) and IFN-α (PBL Biomedical Laboratories)) were measured by ELISA.
Uptake and internalization of IL-26–DNA complexes by pDCs
Purified pDCs were incubated at 37 °C for 3 h with 3 μg/ml Alexa Fluor 488–labeled DNA 
mixed with 1 μM IL-26 at 5 × 104 cells/well in 200 μl RPMI 1640 medium (Gibco) 
supplemented with 10% FCS (Atlanta Biologicals). Cells were then fixed with 4% 
paraformaldehyde, stained for the pDC-specific marker CD123 (anti-CD123–
allophycocyanin, BD Biosciences) and analyzed by flow cytometry (FACS Calibur, BD 
Biosciences). Alternatively, cells were allowed to attach to poly-L-lysine–coated coverslips 
for 3 h, fixed with 4% paraformaldehyde and stained for the pDC-specific marker CD123 
(anti-CD123–phycoerythrin, clone 7G3, BD Biosciences) or the early endosome marker 
CD71 (anti-CD71–biotin, clone M-A712, BD Biosciences, plus streptavidin-phycoerythrin) 
and mounted in ProLong with DAPI (Life Technologies).
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TLR9 reporter gene assay
HEK293 cells that stably co-express a human TLR4 or TLR9 gene and an NF-κB–inducible 
secreted embryonic alkaline phosphatase (SEAP) reporter gene were purchased from 
Invivogen. After TLR4 or TLR9 activation, secreted SEAP levels were detected in the cell-
free supernatant with QUANTI-Blue medium (InvivoGen) and quantified on the basis of 
optical density at 620 nm.
Tissue homogenization for IL-26 ELISA
The skin biopsies were transferred into polypropylene tubes containing 1 ml buffer 
consisting of PBS supplemented with 1 M NaCl and protease inhibitor (Protease Inhibitor 
Cocktail Set III, Merck Millipore) before homogenization was performed with a Polytron PT 
2500 E (Kinematica, Switzerland). The homogenates were then transferred into Protein Low 
Bind Tubes (Eppendorf) and centrifuged at 5,000g for 5 min at 4 °C. The resulting 
supernatant was stored at −20 °C. To determine the concentration of total protein, we used 
the Pierce BCA Protein Assay Kit (Thermo Scientific) according to the manufacturer’s 
protocol. We adjusted the samples’ total protein concentration to 100 μg/ml before we 
measured IL-26 concentrations by ELISA (Cusabio Biotech). We then estimated the 
concentration of IL-26 in the original skin-biopsy sample by dividing the total amount of 
IL-26 measured in each sample by the skin-biopsy volume. The skin-biopsy volume in a 
cylindrical 3-mm punch-biopsy specimen was estimated as follows: h × (πr2) = 3 × (π × 
1.52) = 21.2 mm3 = 21.2 μl.
Statistical analysis
For statistical analyses, we used the two-tailed unpaired Student’s t-test for in vitro 
experiments and the unpaired non-parametric Mann-Whitney U-test for in vivo experiments 
and patient-sample analyses. P < 0.05 was considered significant. Group sizes, 
reproducibility and P values for each experiment are given in figure legends.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
IL-26 is a cationic amphipathic protein that forms oligomers. (a) Protein ribbon of IL-26 
obtained by homology modeling. Six predicted α-helices are indicated as αA–αF and are 
represented in different colors. (b) Color-coded electrostatic potentials mapped onto the 
surfaces of IL-26 (top row) and IL-22 (bottom row). Regions of positive charges are in blue, 
negative charges are in red and hydrophobic charges are in white. (c) Small-angle X-ray 
scattering analysis and rigid-body modeling (via Sasref) of IL-26 suggested the formation of 
elongated tetramers. The four IL-26 molecules (secondary-structure representation) are 
shown in different colors.
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Figure 2. 
IL-26 has direct bactericidal properties. (a) Growth of Pseudomonas aeruginosa ATCC 
27853 (P. aerug.), Escherichia coli O1:K1:H7 (E. coli), Staphylococcus aureus ATCC 6538 
(S. aureus) and Klebsiella pneumoniae O1:K2 (K. pneumo.) in culture with increasing 
concentrations of rhIL-26. (b) Growth of P. aeruginosa in culture with increasing 
concentrations of rhIL-26, rhIL-17 and rhIL-22. (c) Growth kinetics of P. aeruginosa 
cultured with no IL-26, with 10 μM rhIL-26, and with rhIL-26 in the presence of either 
blocking anti–IL-26 or isotype control antibodies (ctl IgG). (d) Membrane potential of P. 
aeruginosa cultured for 24 h as in c and stained with the green fluorescent dye DiOC2(3), 
which forms red fluorescent aggregates in polarized membranes. A loss of red fluorescence 
indicates membrane disruption. The proton ionophore CCCP was used as a positive control. 
(e) Kinetics of membrane potential of P. aeruginosa cultured as in d. (f) P. aeruginosa 
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cultured for 30 min with or without 10 μM rhIL-26 and visualized by scanning electron 
microscopy. Arrows in the top right image show the formation of membrane blebs; arrow in 
the lower right image shows extracellular leakage of bacterial content. (g) Capacity of IL-26 
to bind LPS or LTA as assessed by enzyme-linked immunosorbent assay (ELISA). (h) 
Bacterial loads measured in mouse lungs, spleen and blood collected 3 d after intranasal 
infection with K. pneumoniae (100 CFU) followed by intranasal treatment with 20 μg 
rhIL-26 or 50 μg LL-37. As a control, K. pneumoniae was pretreated with rhIL-26 ex vivo. 
Each data point represents a separate mouse; ††† indicates a mouse that died from 
overwhelming infection within the 3-d period between initial infection and organ collection. 
Data are representative of three (a–c,e), two (g) or four (h) independent experiments and 
were obtained from eight mice per group; error bars represent ±s.d. of duplicate (a–c,e) or 
triplicate (g) wells. Data were statistically analyzed via unpaired non-parametric Mann-
Whitney U-test. *P < 0.001. CFU, colony-forming units.
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Figure 3. 
TH17 cells exert direct antimicrobial activity via the production of IL-26. (a) Real-time PCR 
analysis of IL26, IL17A, IL17F, IL22, IL13 and IFNG mRNA expression by primary TH17, 
TH1, TH2 and TH0 cells generated in vitro from purified naive T cells and re-stimulated by 
plate-bound anti-CD3 and soluble anti-CD28. Cytokine mRNA expression was normalized 
to GAPDH mRNA expression. Each data point represents a separate donor (n = 10–11); 
horizontal bars denote mean values. (b) Growth of P. aeruginosa cultured with supernatants 
of primary TH0 and TH17 cells and measured by microbroth dilution assay. Assays were 
performed with and without blocking anti–IL-26 and control antibodies (Ctl IgG). (c) 
Growth of P. aeruginosa cultured with supernatants of three TH17 cell clones (1G3, 7H1 
and 72G6) transfected with siRNA against IL-26 (siIL26, white bars) or a control siRNA 
(siCtl, black bars). n.s., not significant. (d) IL-26 production by re-stimulated primary TH0 
and TH17 cells and transfected TH17 cell clones as measured by ELISA. Data are 
representative of at least three (b,c) or two (d) independent experiments. Error bars represent 
the s.d. of triplicate wells (b,c). Data were statistically analyzed via unpaired two-tailed 
Student’s t-test; *P < 0.05, **P < 0.01.
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Figure 4. 
IL-26 promotes bacterial killing and concomitant sensing of DNA released by pDCs. (a) 
Confocal microscopy images of DNA–IL-26 complexes (yellow) in cultures of P. 
aeruginosa treated with rhIL-26 and stained with DAPI (green) and anti–IL-26 (red). Images 
shown are representative of three independent experiments. (b,c) Fluorimetric quantification 
of DNA staining by picogreen dye after mixing of bacterial DNA with increasing 
concentrations of IL-26 (b) or 1 μM IL-26, IL-17 or IL-22 (c). A.U., arbitrary units. (d) 
Number of particles formed after mixing of bacterial DNA with 1 μM IL-17, IL-22 or IL-26, 
counted as insoluble precipitates by microscopy. (e) Production of IL-1β, IL-6, TNF and 
IFN-α by PBMCs stimulated overnight with 1 μM IL-26 alone or in complex with bacterial 
DNA (bactDNA, 3 μg ml−1). Bars show mean ± s.d. of pooled data. (f) IFN-α produced by 
human PBMCs, monocytes, macrophages, NK cells, neutrophils, pDCs and pDC-depleted 
PBMCs stimulated overnight with 1 μM IL-26 alone or in complex with bactDNA. Bars 
show mean ± s.d. of pooled data. (g–i) IFN-α produced by pDCs stimulated overnight with 
increasing concentrations of live P. aeruginosa (titrated according to CFU) (g) or of P. 
aeruginosa lysate (titrated according to DNA content) (h) in the presence or not of IL-26 (10 
or 1 μM, respectively). (i) IFN-α produced by pDCs stimulated overnight with P. 
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aeruginosa lysate (1 μg ml−1 DNA) or purified bactDNA (1 μg ml−1) alone or in the 
presence of IL-26, with or without DNase pretreatment. Data are representative of four 
independent experiments (b–d,g–i) or four independent donors (e,f); error bars represent the 
s.d. of triplicate wells (b–d,g–i). Data were statistically analyzed via unpaired two-tailed 
Student’s t-test; *P < 0.05, **P < 0.01.
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Figure 5. 
IL-26 promotes pDC sensing of human DNA released in the context of cell death. (a) Cell 
viability of monocytes, macrophages, NK cells, neutrophils, pDCs and HEK cells as 
determined by staining with 7-AAD after overnight culture in medium alone or in the 
presence of either 10 μM rhIL-26 or undiluted supernatants (SN) of primary TH17 cells. (b) 
IFN-α produced by pDCs stimulated overnight with live or UV-irradiated HEK293 cells in 
the presence or not of 10 μM rhIL-26. (c) Fluorimetric quantification of DNA staining by 
picogreen dye upon mixing of human DNA fragments (huDNA) with increasing 
concentrations of rhIL-26. (d) Visualization of DNA–IL-26 complexes (yellow) formed 
after mixing of human DNA with rhIL-26 and appearing as insoluble precipitates that 
stained with DAPI (green) and anti–IL-26 (red). (e) IFN-α produced by human PBMCs, 
monocytes, macrophages, NK cells, neutrophils, pDCs and pDC-depleted PBMCs 
stimulated overnight with IL-26 alone, human DNA alone or IL-26–human DNA 
complexes. Each data point represents an individual donor (n = 4 for each condition). Bars 
show mean ± s.d. of pooled data. Data were statistically analyzed via unpaired two-tailed 
Student’s t-test; *P < 0.05, **P < 0.0001. (f) IFN-α produced by pDCs stimulated with 
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increasing concentrationsof human DNA either alone or in complex with 1 μM IL-26. In 
panels a–c and f, data are representative of three independent experiments, and error bars 
represent ±s.d. of triplicate wells.
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Figure 6. 
IL-26–DNA complexes are endocytosed via heparan-sulfate proteoglycans and activate 
TLR9 in pDCs. (a) Flow cytometry of CD123+ pDCs stimulated for 4 h with Alexa Fluor 
488–conjugated human DNA (huDNAA488) alone or complexed with increasing 
concentrations of IL-26. (b) Confocal microscopy images of pDCs stimulated with 
huDNAA488 alone or with IL-26–huDNAA488 complexes. We used DAPI to stain the 
nucleus, and we used phycoerythrin-conjugated anti-CD123 to visualize the contour of 
pDCs (left and middle panels) or biotin-conjugated anti-CD71 plus phycoerythrin-
conjugated streptavidin to visualize early endocytic compartments (right panel). (c) Flow 
cytometry of human DNA–positive CD123+ pDCs stimulated for 4 h with huDNAA488 
complexed with IL-26 after pretreatment with 1 μg ml−1 cytochalasin D (Cyto D) to block 
endocytosis, 0.5 μg ml−1 trypsin to cleave membrane proteins and 100 mU Heparinase III to 
cleave surface heparan-sulfate proteoglycans. Cells were also cultured at 4 °C to inhibit 
active internalization processes such as endocytosis. (d) Quantification of human DNA–
positive CD123+ pDCs stimulated as in c. *P < 0.01, **P < 0.001, ***P < 0.0001. (e) IFN-α 
produced by pDCs stimulated overnight with IL-26–human DNA complexes in the presence 
of increasing concentrations of chloroquine to inhibit endosomal TLR activation. (f) 
Fluorimetric quantification of embryonic alkaline phosphatase secreted by HEK293 cells 
transfected with either TLR9 or TLR4 along with an NF-κB–inducible secreted embryonic 
alkaline phosphatase reporter gene and stimulated under the indicated conditions. CpG, 
synthetic phosphothioate TLR9 agonist CpG-2006. *P < 0.0001. Data are representative of 
three independent experiments. Error bars in d–f represent the s.d. of triplicate wells. Data 
were statistically analyzed via unpaired two-tailed Student’s t-test.
Meller et al. Page 28
Nat Immunol. Author manuscript; available in PMC 2016 March 03.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 7. 
TH17 cells activate pDCs via IL-26 production. (a) Confocal microscopy images of 
insoluble DNA–IL-26 particles in supernatants of re-stimulated TH17 cells stained with 
DAPI and unlabeled anti–IL-26 plus Alexa Fluor 546–conjugated mouse anti-IgG. Images 
shown are representative of three independent experiments. (b) DNA–IL-26 particle count 
in supernatants of re-stimulated TH17 and TH0 cells. Each data point represents an 
independent donor (n = 4–6). Horizontal bars represent means. Data were statistically 
analyzed via unpaired two-tailed Student’s t-test; *P < 0.05. (c–g) IFN-α produced by pDCs 
stimulated overnight with (c) various dilutions of TH17 cell–derived supernatants in culture 
medium; (d) supernatants of re-stimulated TH17 or TH0 cells derived from multiple donors 
(n = 9); (e) supernatant derived from TH17 cells re-stimulated in the presence of anti–IL-26, 
anti–IL-17 or DNase I treatment or untreated; (f) TH17 cell supernatants derived from 
multiple donors (n = 3–7), either alone or supplemented by exogenous human DNA (3 μg 
ml−1), with or without blocking anti–IL-26; and (g) supernatants of TH17 cell clones (n = 3) 
transfected with siRNA against IL-26 (siIL26) or a control siRNA (siCtl) supplemented or 
not by human DNA. In a–g, data are representative of at least three independent experiments 
and were statistically analyzed via unpaired two-tailed Student’s t-test; *P < 0.05, **P < 
0.01. Horizontal bars in d, f and g represent means. (h) IL-26 concentrations in healthy skin 
and psoriatic skin lesions measured by ELISA of total skin extracts derived from healthy 
donors (n = 15) or psoriasis patients (n = 15). Each data point represents an individual 
donor. Data were statistically analyzed via unpaired non-parametric Mann-Whitney U-test; 
*P < 0.001.
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Table 1
MIC50 determination of IL-26 antimicrobial activity against several microorganisms
Organism MIC50 of IL-26 (μM)
Pseudomonas aeruginosa (ATCC 27853) 8.6
Escherichia coli (ATCC 11775) 18.6
Staphylococcus aureus (ATCC 6538) 8.8
Enterococcus faecalis (ATCC 29212) >50
Candida albicans (ATCC 24433) >50
MIC50 of IL-26 against P. aeruginosa, E. coli, S. aureus, E. faecalis and C. albicans determined by microbroth dilution assay.
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